hrcak mascot   Srce   HID

Izvorni znanstveni članak

Health and economic burden of skin melanoma in Croatia – cost-of-illness study

Goran Bencina
Marija Buljan
Mirna Šitum
Ranko Stevanović
Vanesa Benković

Puni tekst: engleski, PDF (176 KB) str. 1-1 preuzimanja: 252* citiraj
APA 6th Edition
Bencina, G., Buljan, M., Šitum, M., Stevanović, R. i Benković, V. (2017). Health and economic burden of skin melanoma in Croatia – cost-of-illness study. Acta Dermatovenerologica Croatica, 25 (1), 1-1. Preuzeto s https://hrcak.srce.hr/180898
MLA 8th Edition
Bencina, Goran, et al. "Health and economic burden of skin melanoma in Croatia – cost-of-illness study." Acta Dermatovenerologica Croatica, vol. 25, br. 1, 2017, str. 1-1. https://hrcak.srce.hr/180898. Citirano 24.11.2020.
Chicago 17th Edition
Bencina, Goran, Marija Buljan, Mirna Šitum, Ranko Stevanović i Vanesa Benković. "Health and economic burden of skin melanoma in Croatia – cost-of-illness study." Acta Dermatovenerologica Croatica 25, br. 1 (2017): 1-1. https://hrcak.srce.hr/180898
Harvard
Bencina, G., et al. (2017). 'Health and economic burden of skin melanoma in Croatia – cost-of-illness study', Acta Dermatovenerologica Croatica, 25(1), str. 1-1. Preuzeto s: https://hrcak.srce.hr/180898 (Datum pristupa: 24.11.2020.)
Vancouver
Bencina G, Buljan M, Šitum M, Stevanović R, Benković V. Health and economic burden of skin melanoma in Croatia – cost-of-illness study. Acta Dermatovenerol Croat. [Internet]. 2017 [pristupljeno 24.11.2020.];25(1):1-1. Dostupno na: https://hrcak.srce.hr/180898
IEEE
G. Bencina, M. Buljan, M. Šitum, R. Stevanović i V. Benković, "Health and economic burden of skin melanoma in Croatia – cost-of-illness study", Acta Dermatovenerologica Croatica, vol.25, br. 1, str. 1-1, 2017. [Online]. Dostupno na: https://hrcak.srce.hr/180898. [Citirano: 24.11.2020.]

Sažetak

Melanoma incidence is increasing, especially in the younger population. The aim of this study was to investigate the cost of this disease in the Croatian population and to identify costs through types of care and types of costs. The secondary goal was to estimate the prevalence of certain types of melanoma (as well as staging distribution) and to connect each stage and its prevalence in Croatia to related costs. A cost-of-illness analysis was performed, mainly including direct costs (monitoring, drugs, primary health care services, hospitalizations, and diagnostics). The calculations were based on data collected from Sestre milosrdnice University Hospital Center in Zagreb and from Cancer Registry Data. The number of patients with melanoma was calculated using the Markov model for melanoma staging and 5-year survival. The estimated total prevalence of melanoma in 2011 in Croatia was 2,180. The total cost of melanoma was estimated to 1,063,488 EUR, with 46% used for hospitalization and chemotherapy, 10% for dermatoscopy, and the remaining 17% being monitoring costs. The average cost per patient was estimated to range between 98 and 4,333 EUR depending on the stage of the disease. The cost of melanoma in the adult population in Croatia in a one-year timeframe accounted for as much as 0.04% of the total Croatian national health care budget for 2011. Study findings indicate the need for a clear strategy to achieve regular screening in order to detect the disease at an early stage.

 

Hrčak ID: 180898

URI
https://hrcak.srce.hr/180898

Posjeta: 404 *